SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
XenoPort, Inc. Reports Favorable Metabolism and Pharmacokinetics of XP23829, a Novel Fumaric Acid Ester, in Phase 1 Trial